{"id":244154,"date":"2021-09-29T12:42:03","date_gmt":"2021-09-29T16:42:03","guid":{"rendered":"https:\/\/oncubanews.com\/en\/?p=244154"},"modified":"2021-09-29T12:42:03","modified_gmt":"2021-09-29T16:42:03","slug":"gammaglobulin-clinical-trial-shows-satisfactory-results-in-treatment-of-covid-19-patients","status":"publish","type":"post","link":"https:\/\/oncubanews.com\/en\/coronavirus\/gammaglobulin-clinical-trial-shows-satisfactory-results-in-treatment-of-covid-19-patients\/","title":{"rendered":"Gammaglobulin clinical trial shows satisfactory results in treatment of COVID-19 patients"},"content":{"rendered":"<p><span style=\"font-weight: 400;\">The phase I clinical trial with the product Gammaglobulin showed encouraging results in terms of safety, reduction of lung lesions and viral negativization in <\/span><a href=\"https:\/\/oncubanews.com\/en\/coronavirus\" target=\"_blank\" rel=\"noopener\"><span style=\"font-weight: 400;\">COVID-19<\/span><\/a><span style=\"font-weight: 400;\"> patients, said Cuban experts in charge of the study.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">The drug was developed by the enterprise Laboratorios AICA in conjunction with the Ministry of Public Health (MINSAP), based on blood donations from convalescents of the disease caused by the SARS-CoV-2 coronavirus, Cubadebate reported.<\/span><\/p>\n<blockquote class=\"twitter-tweet\" data-width=\"500\" data-dnt=\"true\">\n<p lang=\"es\" dir=\"ltr\">La Empresa Laboratorios <a href=\"https:\/\/twitter.com\/hashtag\/AICA?src=hash&amp;ref_src=twsrc%5Etfw\">#AICA<\/a> de conjunto con el Ministerio de Salud P\u00fablica (<a href=\"https:\/\/twitter.com\/hashtag\/MINSAP?src=hash&amp;ref_src=twsrc%5Etfw\">#MINSAP<\/a>) desarrollan un <a href=\"https:\/\/twitter.com\/hashtag\/EnsayoCl%C3%ADnico?src=hash&amp;ref_src=twsrc%5Etfw\">#EnsayoCl\u00ednico<\/a> con el producto <a href=\"https:\/\/twitter.com\/hashtag\/Gammaglobulina?src=hash&amp;ref_src=twsrc%5Etfw\">#Gammaglobulina<\/a> anti-SARS-CoV-2 con alentadores resultados.<a href=\"https:\/\/twitter.com\/hashtag\/COVID19?src=hash&amp;ref_src=twsrc%5Etfw\">#COVID19<\/a> <a href=\"https:\/\/twitter.com\/hashtag\/CienciaCubana?src=hash&amp;ref_src=twsrc%5Etfw\">#CienciaCubana<\/a><a href=\"https:\/\/twitter.com\/MINSAPCuba?ref_src=twsrc%5Etfw\">@MINSAPCuba<\/a> <a href=\"https:\/\/twitter.com\/AicaLaboratorio?ref_src=twsrc%5Etfw\">@AicaLaboratorio<\/a> <a href=\"https:\/\/t.co\/MTj0dbj2yj\">https:\/\/t.co\/MTj0dbj2yj<\/a><\/p>\n<p>&mdash; RedCubanaDeLaCiencia (@RedCienciaCuba) <a href=\"https:\/\/twitter.com\/RedCienciaCuba\/status\/1442846930665619462?ref_src=twsrc%5Etfw\">September 28, 2021<\/a><\/p><\/blockquote>\n<p><script async src=\"https:\/\/platform.twitter.com\/widgets.js\" charset=\"utf-8\"><\/script><\/p>\n<p><span style=\"font-weight: 400;\">Captain Beatriz Amat, principal researcher of the trial carried out at the Doctor Luis D\u00edaz Soto Central Military Hospital, explained that the study included 21 patients older than 19 years with severe symptoms of COVID-19, 10 of whom formed the control group and 11 received the drug.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">The doctor stated that 72 hours after starting the treatment, the initial symptoms in the patients decreased and the PCR test was negative, while the lung lesions were progressively reduced in the image studies, the source indicated.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Moreover, the specialist in Immunology and Comprehensive General Medicine affirmed that no adverse events were recorded, and none of the treated patients required ventilatory assistance, nor did they reach critical stages of the contagious disease.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">For her part, Master of Science Maritza Gonz\u00e1lez said that the anti-SARS-CoV-2 Gamma globulin is a blood product manufactured in the Serums and Blood Products business unit belonging to the AICA Laboratories.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">She explained that the product is obtained from a concentrate of antibodies derived from a pool of plasma from volunteer donors convalescing from the virus, who during the infection were classified as moderately, seriously and critically ill; in addition to people immunized with the Soberana Plus vaccine.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Cited by the source, the specialist stressed that her enterprise has the necessary and adequate capacities to increase the manufacture of the drug, but so far there are not enough voluntary blood donations.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">During the pandemic, Cuba opted to develop its own drugs to treat COVID-19 patients and its internationally recognized biotechnology and pharmaceutical industry has met expectations.<\/span><\/p>\n<blockquote class=\"wp-embedded-content\" data-secret=\"HQAQxVHnjJ\"><p><a href=\"https:\/\/oncubanews.com\/en\/cuba\/cuban-medicines-against-covid-19-i\/\">Cuban medicines against COVID-19 (I)<\/a><\/p><\/blockquote>\n<p><iframe loading=\"lazy\" class=\"wp-embedded-content\" sandbox=\"allow-scripts\" security=\"restricted\" style=\"position: absolute; clip: rect(1px, 1px, 1px, 1px);\" title=\"&#8220;Cuban medicines against COVID-19 (I)&#8221; &#8212; OnCubaNews English\" src=\"https:\/\/oncubanews.com\/en\/cuba\/cuban-medicines-against-covid-19-i\/embed\/#?secret=hYGngmO9rc#?secret=HQAQxVHnjJ\" data-secret=\"HQAQxVHnjJ\" width=\"500\" height=\"282\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\"><\/iframe><\/p>\n<p><span style=\"font-weight: 400;\">Products such as recombinant interferon Alpha 2B, CIGB 258 and Biomodulin T, and entities such as the BioCubaFarma business group, the Center for Genetic Engineering and Biotechnology (CIGB) and the Finlay Institute are systematically mentioned in the media, and their directors \u2014 who in turn have become spokespeople for those who remain working in the shadows \u2014 have become public figures at a time when true contributions in favor of life are gaining ground in the face of the usual celebrity of the frivolous.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">In addition, Cuban scientists have managed to develop three COVID-19 vaccines that showed high efficacy in clinical trials and are currently used in the immunization of the island\u2019s entire population, scheduled to conclude this year.<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The drug was developed by the enterprise Laboratorios AICA in conjunction with the Ministry of Public Health (MINSAP), based on blood donations from convalescents of the disease caused by the SARS-CoV-2 coronavirus.<\/p>\n","protected":false},"author":3134,"featured_media":244156,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[33393],"tags":[29532,15273],"ppma_author":[33546],"class_list":["post-244154","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-coronavirus","tag-coronavirus-in-cuba","tag-cuban-science"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Gammaglobulin clinical trial shows satisfactory results in treatment of COVID-19 patients | OnCubaNews English<\/title>\n<meta name=\"description\" content=\"The drug was developed by the enterprise Laboratorios AICA in conjunction with the Ministry of Public Health (MINSAP), based on blood donations from convalescents of the disease caused by the SARS-CoV-2 coronavirus.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/oncubanews.com\/en\/coronavirus\/gammaglobulin-clinical-trial-shows-satisfactory-results-in-treatment-of-covid-19-patients\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Gammaglobulin clinical trial shows satisfactory results in treatment of COVID-19 patients | OnCubaNews English\" \/>\n<meta property=\"og:description\" content=\"The drug was developed by the enterprise Laboratorios AICA in conjunction with the Ministry of Public Health (MINSAP), based on blood donations from convalescents of the disease caused by the SARS-CoV-2 coronavirus.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/oncubanews.com\/en\/coronavirus\/gammaglobulin-clinical-trial-shows-satisfactory-results-in-treatment-of-covid-19-patients\/\" \/>\n<meta property=\"og:site_name\" content=\"OnCubaNews English\" \/>\n<meta property=\"article:published_time\" content=\"2021-09-29T16:42:03+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/oncubanews.com\/en\/wp-content\/uploads\/2021\/09\/Hospital-Ciego-de-Avila-750x421-1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"750\" \/>\n\t<meta property=\"og:image:height\" content=\"421\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"OnCuba Staff\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"OnCuba Staff\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/oncubanews.com\\\/en\\\/coronavirus\\\/gammaglobulin-clinical-trial-shows-satisfactory-results-in-treatment-of-covid-19-patients\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/oncubanews.com\\\/en\\\/coronavirus\\\/gammaglobulin-clinical-trial-shows-satisfactory-results-in-treatment-of-covid-19-patients\\\/\"},\"author\":{\"name\":\"OnCuba Staff\",\"@id\":\"https:\\\/\\\/oncubanews.com\\\/en\\\/#\\\/schema\\\/person\\\/d7171bf311032ab1f557dd8332e714af\"},\"headline\":\"Gammaglobulin clinical trial shows satisfactory results in treatment of COVID-19 patients\",\"datePublished\":\"2021-09-29T16:42:03+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/oncubanews.com\\\/en\\\/coronavirus\\\/gammaglobulin-clinical-trial-shows-satisfactory-results-in-treatment-of-covid-19-patients\\\/\"},\"wordCount\":484,\"commentCount\":0,\"image\":{\"@id\":\"https:\\\/\\\/oncubanews.com\\\/en\\\/coronavirus\\\/gammaglobulin-clinical-trial-shows-satisfactory-results-in-treatment-of-covid-19-patients\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/oncubanews.com\\\/en\\\/wp-content\\\/uploads\\\/2021\\\/09\\\/Hospital-Ciego-de-Avila-750x421-1.jpg\",\"keywords\":[\"coronavirus in Cuba\",\"Cuban science\"],\"articleSection\":[\"Coronavirus\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/oncubanews.com\\\/en\\\/coronavirus\\\/gammaglobulin-clinical-trial-shows-satisfactory-results-in-treatment-of-covid-19-patients\\\/#respond\"]}],\"copyrightYear\":\"2021\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/oncubanews.com\\\/en\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/oncubanews.com\\\/en\\\/coronavirus\\\/gammaglobulin-clinical-trial-shows-satisfactory-results-in-treatment-of-covid-19-patients\\\/\",\"url\":\"https:\\\/\\\/oncubanews.com\\\/en\\\/coronavirus\\\/gammaglobulin-clinical-trial-shows-satisfactory-results-in-treatment-of-covid-19-patients\\\/\",\"name\":\"Gammaglobulin clinical trial shows satisfactory results in treatment of COVID-19 patients | OnCubaNews English\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/oncubanews.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/oncubanews.com\\\/en\\\/coronavirus\\\/gammaglobulin-clinical-trial-shows-satisfactory-results-in-treatment-of-covid-19-patients\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/oncubanews.com\\\/en\\\/coronavirus\\\/gammaglobulin-clinical-trial-shows-satisfactory-results-in-treatment-of-covid-19-patients\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/oncubanews.com\\\/en\\\/wp-content\\\/uploads\\\/2021\\\/09\\\/Hospital-Ciego-de-Avila-750x421-1.jpg\",\"datePublished\":\"2021-09-29T16:42:03+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/oncubanews.com\\\/en\\\/#\\\/schema\\\/person\\\/d7171bf311032ab1f557dd8332e714af\"},\"description\":\"The drug was developed by the enterprise Laboratorios AICA in conjunction with the Ministry of Public Health (MINSAP), based on blood donations from convalescents of the disease caused by the SARS-CoV-2 coronavirus.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/oncubanews.com\\\/en\\\/coronavirus\\\/gammaglobulin-clinical-trial-shows-satisfactory-results-in-treatment-of-covid-19-patients\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/oncubanews.com\\\/en\\\/coronavirus\\\/gammaglobulin-clinical-trial-shows-satisfactory-results-in-treatment-of-covid-19-patients\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/oncubanews.com\\\/en\\\/coronavirus\\\/gammaglobulin-clinical-trial-shows-satisfactory-results-in-treatment-of-covid-19-patients\\\/#primaryimage\",\"url\":\"https:\\\/\\\/oncubanews.com\\\/en\\\/wp-content\\\/uploads\\\/2021\\\/09\\\/Hospital-Ciego-de-Avila-750x421-1.jpg\",\"contentUrl\":\"https:\\\/\\\/oncubanews.com\\\/en\\\/wp-content\\\/uploads\\\/2021\\\/09\\\/Hospital-Ciego-de-Avila-750x421-1.jpg\",\"width\":750,\"height\":421,\"caption\":\"Photo: Alejandro Garc\u00eda\\\/invasor.cu\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/oncubanews.com\\\/en\\\/coronavirus\\\/gammaglobulin-clinical-trial-shows-satisfactory-results-in-treatment-of-covid-19-patients\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Portada\",\"item\":\"https:\\\/\\\/oncubanews.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Gammaglobulin clinical trial shows satisfactory results in treatment of COVID-19 patients\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/oncubanews.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/oncubanews.com\\\/en\\\/\",\"name\":\"OnCubaNews English\",\"description\":\"Revista sobre Cuba\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/oncubanews.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/oncubanews.com\\\/en\\\/#\\\/schema\\\/person\\\/d7171bf311032ab1f557dd8332e714af\",\"name\":\"OnCuba Staff\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/4b4c4d6109baadde898bb1af22ea4a4af5f4417b86a5d1800bf17531bfb128fc?s=96&r=g17310096d4dde63ebae0e54fbb19218a\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/4b4c4d6109baadde898bb1af22ea4a4af5f4417b86a5d1800bf17531bfb128fc?s=96&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/4b4c4d6109baadde898bb1af22ea4a4af5f4417b86a5d1800bf17531bfb128fc?s=96&r=g\",\"caption\":\"OnCuba Staff\"},\"url\":\"https:\\\/\\\/oncubanews.com\\\/en\\\/author\\\/oncuba-editorial-staff\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Gammaglobulin clinical trial shows satisfactory results in treatment of COVID-19 patients | OnCubaNews English","description":"The drug was developed by the enterprise Laboratorios AICA in conjunction with the Ministry of Public Health (MINSAP), based on blood donations from convalescents of the disease caused by the SARS-CoV-2 coronavirus.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/oncubanews.com\/en\/coronavirus\/gammaglobulin-clinical-trial-shows-satisfactory-results-in-treatment-of-covid-19-patients\/","og_locale":"en_US","og_type":"article","og_title":"Gammaglobulin clinical trial shows satisfactory results in treatment of COVID-19 patients | OnCubaNews English","og_description":"The drug was developed by the enterprise Laboratorios AICA in conjunction with the Ministry of Public Health (MINSAP), based on blood donations from convalescents of the disease caused by the SARS-CoV-2 coronavirus.","og_url":"https:\/\/oncubanews.com\/en\/coronavirus\/gammaglobulin-clinical-trial-shows-satisfactory-results-in-treatment-of-covid-19-patients\/","og_site_name":"OnCubaNews English","article_published_time":"2021-09-29T16:42:03+00:00","og_image":[{"width":750,"height":421,"url":"https:\/\/oncubanews.com\/en\/wp-content\/uploads\/2021\/09\/Hospital-Ciego-de-Avila-750x421-1.jpg","type":"image\/jpeg"}],"author":"OnCuba Staff","twitter_card":"summary_large_image","twitter_misc":{"Written by":"OnCuba Staff","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/oncubanews.com\/en\/coronavirus\/gammaglobulin-clinical-trial-shows-satisfactory-results-in-treatment-of-covid-19-patients\/#article","isPartOf":{"@id":"https:\/\/oncubanews.com\/en\/coronavirus\/gammaglobulin-clinical-trial-shows-satisfactory-results-in-treatment-of-covid-19-patients\/"},"author":{"name":"OnCuba Staff","@id":"https:\/\/oncubanews.com\/en\/#\/schema\/person\/d7171bf311032ab1f557dd8332e714af"},"headline":"Gammaglobulin clinical trial shows satisfactory results in treatment of COVID-19 patients","datePublished":"2021-09-29T16:42:03+00:00","mainEntityOfPage":{"@id":"https:\/\/oncubanews.com\/en\/coronavirus\/gammaglobulin-clinical-trial-shows-satisfactory-results-in-treatment-of-covid-19-patients\/"},"wordCount":484,"commentCount":0,"image":{"@id":"https:\/\/oncubanews.com\/en\/coronavirus\/gammaglobulin-clinical-trial-shows-satisfactory-results-in-treatment-of-covid-19-patients\/#primaryimage"},"thumbnailUrl":"https:\/\/oncubanews.com\/en\/wp-content\/uploads\/2021\/09\/Hospital-Ciego-de-Avila-750x421-1.jpg","keywords":["coronavirus in Cuba","Cuban science"],"articleSection":["Coronavirus"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/oncubanews.com\/en\/coronavirus\/gammaglobulin-clinical-trial-shows-satisfactory-results-in-treatment-of-covid-19-patients\/#respond"]}],"copyrightYear":"2021","copyrightHolder":{"@id":"https:\/\/oncubanews.com\/en\/#organization"}},{"@type":"WebPage","@id":"https:\/\/oncubanews.com\/en\/coronavirus\/gammaglobulin-clinical-trial-shows-satisfactory-results-in-treatment-of-covid-19-patients\/","url":"https:\/\/oncubanews.com\/en\/coronavirus\/gammaglobulin-clinical-trial-shows-satisfactory-results-in-treatment-of-covid-19-patients\/","name":"Gammaglobulin clinical trial shows satisfactory results in treatment of COVID-19 patients | OnCubaNews English","isPartOf":{"@id":"https:\/\/oncubanews.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/oncubanews.com\/en\/coronavirus\/gammaglobulin-clinical-trial-shows-satisfactory-results-in-treatment-of-covid-19-patients\/#primaryimage"},"image":{"@id":"https:\/\/oncubanews.com\/en\/coronavirus\/gammaglobulin-clinical-trial-shows-satisfactory-results-in-treatment-of-covid-19-patients\/#primaryimage"},"thumbnailUrl":"https:\/\/oncubanews.com\/en\/wp-content\/uploads\/2021\/09\/Hospital-Ciego-de-Avila-750x421-1.jpg","datePublished":"2021-09-29T16:42:03+00:00","author":{"@id":"https:\/\/oncubanews.com\/en\/#\/schema\/person\/d7171bf311032ab1f557dd8332e714af"},"description":"The drug was developed by the enterprise Laboratorios AICA in conjunction with the Ministry of Public Health (MINSAP), based on blood donations from convalescents of the disease caused by the SARS-CoV-2 coronavirus.","breadcrumb":{"@id":"https:\/\/oncubanews.com\/en\/coronavirus\/gammaglobulin-clinical-trial-shows-satisfactory-results-in-treatment-of-covid-19-patients\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/oncubanews.com\/en\/coronavirus\/gammaglobulin-clinical-trial-shows-satisfactory-results-in-treatment-of-covid-19-patients\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/oncubanews.com\/en\/coronavirus\/gammaglobulin-clinical-trial-shows-satisfactory-results-in-treatment-of-covid-19-patients\/#primaryimage","url":"https:\/\/oncubanews.com\/en\/wp-content\/uploads\/2021\/09\/Hospital-Ciego-de-Avila-750x421-1.jpg","contentUrl":"https:\/\/oncubanews.com\/en\/wp-content\/uploads\/2021\/09\/Hospital-Ciego-de-Avila-750x421-1.jpg","width":750,"height":421,"caption":"Photo: Alejandro Garc\u00eda\/invasor.cu"},{"@type":"BreadcrumbList","@id":"https:\/\/oncubanews.com\/en\/coronavirus\/gammaglobulin-clinical-trial-shows-satisfactory-results-in-treatment-of-covid-19-patients\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Portada","item":"https:\/\/oncubanews.com\/en\/"},{"@type":"ListItem","position":2,"name":"Gammaglobulin clinical trial shows satisfactory results in treatment of COVID-19 patients"}]},{"@type":"WebSite","@id":"https:\/\/oncubanews.com\/en\/#website","url":"https:\/\/oncubanews.com\/en\/","name":"OnCubaNews English","description":"Revista sobre Cuba","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/oncubanews.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/oncubanews.com\/en\/#\/schema\/person\/d7171bf311032ab1f557dd8332e714af","name":"OnCuba Staff","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/4b4c4d6109baadde898bb1af22ea4a4af5f4417b86a5d1800bf17531bfb128fc?s=96&r=g17310096d4dde63ebae0e54fbb19218a","url":"https:\/\/secure.gravatar.com\/avatar\/4b4c4d6109baadde898bb1af22ea4a4af5f4417b86a5d1800bf17531bfb128fc?s=96&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/4b4c4d6109baadde898bb1af22ea4a4af5f4417b86a5d1800bf17531bfb128fc?s=96&r=g","caption":"OnCuba Staff"},"url":"https:\/\/oncubanews.com\/en\/author\/oncuba-editorial-staff\/"}]}},"authors":[{"term_id":33546,"user_id":3134,"is_guest":0,"slug":"oncuba-editorial-staff","display_name":"OnCuba Staff","avatar_url":"https:\/\/secure.gravatar.com\/avatar\/4b4c4d6109baadde898bb1af22ea4a4af5f4417b86a5d1800bf17531bfb128fc?s=96&r=g","0":null,"1":"","2":"","3":"","4":"","5":"","6":"","7":"","8":""}],"_links":{"self":[{"href":"https:\/\/oncubanews.com\/en\/wp-json\/wp\/v2\/posts\/244154","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/oncubanews.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/oncubanews.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/oncubanews.com\/en\/wp-json\/wp\/v2\/users\/3134"}],"replies":[{"embeddable":true,"href":"https:\/\/oncubanews.com\/en\/wp-json\/wp\/v2\/comments?post=244154"}],"version-history":[{"count":0,"href":"https:\/\/oncubanews.com\/en\/wp-json\/wp\/v2\/posts\/244154\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/oncubanews.com\/en\/wp-json\/wp\/v2\/media\/244156"}],"wp:attachment":[{"href":"https:\/\/oncubanews.com\/en\/wp-json\/wp\/v2\/media?parent=244154"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/oncubanews.com\/en\/wp-json\/wp\/v2\/categories?post=244154"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/oncubanews.com\/en\/wp-json\/wp\/v2\/tags?post=244154"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/oncubanews.com\/en\/wp-json\/wp\/v2\/ppma_author?post=244154"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}